Hemocompatibility of hyaluronan enhanced linear low density polyethylene for blood contacting applications

Abstract

Despite their overall success, different blood-contacting medical devices such as heart valves, stents, and so forth, are still plagued with hemocompatibility issues which often result in the need for subsequent replacement and/or life-long anticoagulation therapy. Consequently, there is a significant interest in developing biomaterials that can address these issues. Polymeric-based materials have been proposed for use in many applications due to their ability to be finely tuned through manufacturing and surface modification to enhance hemocompatibility. In this study, we have developed a novel, hydrophilic biomaterial comprised of an interpenetrating polymer network (IPN) of hyaluronan (HA) and linear low density polyethylene (LLDPE). HA is a highly lubricous, anionic polysaccharide ubiquitously found in the human body. It is currently being investigated for a vast array of biomedical applications including cardiovascular therapies such as hydrogel-based regenerative cell therapies for myocardial infarction, HA-coated stents, and surface modifications of polyurethane and metals for use in blood-contacting implants. The aim of this study was to assess the in vitro thrombogenic response of the hydrophilic polymer surface, HA-LLDPE for future potential use as flexible heart valve leaflets. The results indicate that HA-LLDPE is non-toxic and reduces thromobogenicity as compared to LLDPE surfaces, asserting its feasibility for use as a blood-contacting biomaterial. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 1964-1975, 2018.

An Effective Translation: The Development of Hyaluronan-Based Medical Products From the Physicochemical, and Preclinical Aspects

“…For example: cardiovascular devices (Turner et al, 2004 ), or acute wound dressings such as Hylan® (Longinotti, 2014 ), while genotoxicity assessment is recommended or required for implanted devices which are in contact with tissues for more than 24 h or more than 30 days, respectively: as an example, dermal fillers (De Boulle et al, 2013 ). Devices utilizing native HA are, in general, safe with no hemocompatibility (Simon-Walker et al, 2017 ), or genotoxic issues (Strand et al, 2012 ).…”

Wettability of DPPC Monolayers Deposited from the Titanium Dioxide–Chitosan–Hyaluronic Acid Subphases on Glass

“…To improve the biocompatibility of the systems, hyaluronic acid (HA) can be added. It is a hydrophilic polysaccharide found in the extracellular matrix of living organisms [13]. This biopolymer is often used for medical applications due to its non-toxicity, film-forming capability, bioactivity, biodegradability, and anticoagulant properties [13][14][15].…”

“…It is a hydrophilic polysaccharide found in the extracellular matrix of living organisms [13]. This biopolymer is often used for medical applications due to its non-toxicity, film-forming capability, bioactivity, biodegradability, and anticoagulant properties [13][14][15]. HA existing as a polyanion under physiological pH strongly interacts with Ch (cationic polysaccharide) via electrostatic forces to form the polymeric network.…”

Preliminary hemocompatibility assessment of an innovative material for blood contacting surfaces

“…Platelet activation is a sensitive tool to test bloodcompatibility of synthetic materials [18,19]. Platelet activation can be triggered upon contact with any surface different from the healthy endothelium: both adhesion and consequent activation have been measured by microscopy [20,21]. In other studies, hemocompatibility was investigated by assessing platelet adhesion and complement activation [22].…”